๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Xingtai
Clinical trial register · China

Clinical Trials in Xingtai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Tianjin Medical University Second Hospital4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.3 Tasly Pharmaceutical Group Co., Ltd2 Arrowhead Pharmaceuticals2 Beijing Tiantan Hospital2
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Xingtai

26 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Mindfulness Intervention for Emotional Distress (MIED) in Patients With GERD
NCT07667894Gastroesophageal Reflux Disease, Emotional Distress
Xinghua Liu
Not applicable
500
Beijing, Baiyin, Shenzhen, Guiyang, Xingtai, Xinle, Chifeng, Hohhot
2026-06-29
Recruiting
A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis
NCT07551427Myelofibrosis
DrugRovadicitinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
51
Hefei, Fuzhou, Guangzhou, Nanning, Cangzhou, Chengde, Shijiazhuang, Xingtai
2026-06-18
Not yet open
Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?
NCT07625527Bladder (Urothelial, Transitional Cell) Cancer, Non Muscle Invasive Bladder Cancer
Tianjin Medical University Second Hospital
Phase 2
120
Tianjin, Xingtai
2026-05-30
Recruiting
Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation
NCT07444372Obstructive Sleep Apnea, Sleep Disorder (Disorder), Atrial Fibrillation (AF), Sleep Disordered Breathing (SDB)
Beijing Anzhen Hospital
Not applicable
658
Beijing, Fuzhou, Zhangzhou, Nanning, Langfang, Shijiazhuang, Xingtai, Harbin
2026-05-12
Recruiting
Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
NCT07475403Bladder Cancer, Liquid Biopsy, Immunotherapy
Tianjin Medical University Second Hospital
Phase 2
53
Tianjin, Xingtai
2026-03-16
Recruiting
Phase II Trial of RC1416 Injection in Asthma
NCT07403487Moderate to Severe Asthma
DrugRC1416
Nanjing RegeneCore Biotech Co., Ltd.
Phase 2
195
Anqing, Suzhou, Beijing, Chongqing, Lanzhou, Shijiazhuang, Tangshan, Xingtai
2026-03-10
Recruiting
CAS for Stenosis With High-risk Features for CEA
NCT07370246Carotid Artery Stenosis, Carotid Artery Stenting
Beijing Tiantan Hospital
Not applicable
212
Beijing, Chongqing, Nanning, Guiyang, Shijiazhuang, Xingtai, Wuhan, Hohhot
2026-03-06
Recruiting
Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
NCT07401199Gastric Cancer (GC), Locally Advanced Gastric Cancer
Qun Zhao
Observational
2,000
Fuyang, Cangzhou, Hengshui, Xingtai, Wuhan, Yichang, Baoding, Shijiazhuang
2026-02-05
Recruiting
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
NCT07317934Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
DrugAflibercept
Innostellar Biotherapeutics Co.,Ltd
Phase 3
388
Hefei, Beijing, Chongqing, Guangzhou, Shantou, Zhongshan, Xingtai, Harbin
2026-01-14
Not yet open
A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
NCT07156617Hepatocellular Carcinoma (HCC)
Xuhua Duan
Observational
2,000
Haikou, Xingtai, Dengzhou, Jiaozuo, Kaifeng, Luoyang, Shangqiu, Zhengzhou
2025-10-01
Recruiting
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
NCT07187635Bladder Cancer, Liquid Biopsy, Repeat Transurethral Resection of Bladder Tumor
Tianjin Medical University Second Hospital
Not applicable
196
Nanchang, Guangzhou, Xingtai, Kunming, Shanghai, Tianjin
2025-09-28
Recruiting
Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer
NCT07180212Bladder Cancer, Liquid Biopsy, Cystoscopy
Tianjin Medical University Second Hospital
Not applicable
360
Xingtai, Guangzhou, Haerbin, Kunming, Nanchang, Tianjin
2025-09-20
Not yet open
Phase III Trial of Susu Zhike Granules in Children With Cold-cough Syndrome for Acute Cough Treatment
NCT06773117Cough
Tasly Pharmaceutical Group Co., Ltd
Phase 3
360
Hefei, Chongqing, Guangzhou, Zunyi, Xingtai, Kaifeng, Nanyang, Sanmenxia
2025-09-01
Not yet open
Effectiveness of Auricular Acupuncture for Migraine
NCT07024511Migraine
Universiti Tunku Abdul Rahman
Not applicable
156
Handan, Xingtai
2025-07-01
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Olaparib·Doxorubicin·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
2,400
Hefei, Beijing, Xiamen, Guangzhou, Jiangmen, Liuzhou, Nanning, Xingtai
2025-06-30
Recruiting
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
NCT06822790Hypertriglyceridemia
DrugPlozasiran
Arrowhead Pharmaceuticals
Phase 3
869
Bengbu, Beijing, Guangzhou, Liuzhou, Xingtai, Luoyang, Changsha, Wuhan
2025-04-09
Not yet open
To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)
NCT06888492Wet Age-related Macular Degeneration (wAMD), Wet Age-related Macular Degeneration
Guangzhou Jiayin Biotech Ltd
Phase EARLY_PHASE1
8
Xingtai, Yiwu
2025-03-28
Recruiting
A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome
NCT06696261Postprandial Distress Syndrome
Tasly Pharmaceutical Group Co., Ltd
Phase 3
342
Beijing, Lanzhou, Guiyang, Shijiazhuang, Xingtai, Baoding, Luoyang, Changchun
2025-02-27
Active, closed
Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer
NCT06702618Breast Cancer
DrugsTQB3616·Fulvestrant
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
33
Bengbu, Jiangmen, Xingtai, Harbin, Luohe, Changsha, Nanjing, Nantong
2025-02-20
Recruiting
Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.
NCT07732738Obesity
China-Japan Friendship Hospital
Not applicable
400
Xingtai, Zhengzhou, Baotou, Jinan, Datong, Kunming, Beijing
2025-01-01
Active, closed
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
NCT06347003Severe Hypertriglyceridemia
DrugPlozasiran
Arrowhead Pharmaceuticals
Phase 3
446
Bengbu, Beijing, Guangzhou, Guanzhou, Liuzhou, Xingtai, Luoyang, Wuhan
2024-07-22
Active, closed
A Study of IL4Rฮฑ Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).
NCT06315426Allergic Rhinitis
DrugGR1802
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 2
240
Langfang, Xingtai, Zhengzhou, Jingzhou, Wuhan, Jinan, Liaocheng, Changzhi
2024-03-24
Recruiting
A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)
NCT06122831Myelofibrosis
DrugRovadicitinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
92
Guangzhou, Nanning, Cangzhou, Chengde, Tangshan, Xingtai, Harbin, Zhengzhou
2023-12-12
Recruiting
The Effects of Time Points to Cease Parenteral Nutrition and IGF-1 on Very Low Birth Weight Infants
NCT06071403Growth Retardation
Peking University
Observational
416
Xingtai
2023-07-01
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
14,012
Guangzhou, Nanning, Cangzhou, Shijiazhuang, Tangshan, Xingtai, Daqing, Harbin
2023-03-09
Recruiting
Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial
NCT04948749ICAD - Intracranial Atherosclerotic Disease, ICAS - Intracranial Atherosclerosis, Drug-eluting Stent, Stroke
Beijing Tiantan Hospital
Not applicable
358
Beijing, Cangzhou, Tangshan, Xingtai, Wuhan, Baotou, Hohhot, Tongliao
2021-07-02
Rows per page Showing 1–26 of 26
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/xingtai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 26 of those studies with a site in Xingtai.

How many clinical trials are recruiting in Xingtai?

17 of the 26 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Xingtai), 26 studies
PhaseStudiesRecruitingShare
Not applicable8730.8%
Phase 37426.9%
Phase 26323.1%
Observational3211.5%
Phase 1/2113.8%
Phase EARLY_PHASE1103.8%

Most active sponsors

Lead sponsors with the most studies (Xingtai)
Lead sponsorStudiesRecruiting
Tianjin Medical University Second Hospital43
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.32
Arrowhead Pharmaceuticals21
Beijing Tiantan Hospital22
Tasly Pharmaceutical Group Co., Ltd21
Beijing Anzhen Hospital11
China-Japan Friendship Hospital11
Genrix (Shanghai) Biopharmaceutical Co., Ltd.10
Guangzhou Jiayin Biotech Ltd10
Innostellar Biotherapeutics Co.,Ltd11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.